Tranylcypromine
Tranylcypromine is an MAOI antidepressant used to treat major depressive disorder in adults who haven't responded well to other antidepressants.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 7 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Tranylcypromine (Parnate) is a strong MAOI antidepressant, permanently blocking the enzyme monoamine oxidase to boost brain chemical messengers, reserved for adults with major depressive disorder that other antidepressants have not helped, a specialist option around since the early 1960s and available as a generic. Trouble sleeping, dry mouth and dizziness on standing are the side effects people notice most. The boxed warning covers suicidal thoughts in young people and hypertensive crisis (a dangerous blood pressure spike) from tyramine-rich foods or certain drugs, so a sudden severe headache, stiff neck or pounding heartbeat needs emergency care. Serotonin syndrome is the other danger, so clear every new medicine or supplement with your pharmacist.
Clinical pearls
- The tyramine diet lasts two weeks past your last dose, so keep skipping aged cheese, tap beer, sauerkraut and soy sauce.
- Many cold, sinus and weight-loss products contain pseudoephedrine, phenylephrine or dextromethorphan, all off-limits, so read every label.
- Tell any surgeon or anesthesia team you take it, since it affects blood pressure during surgery and may need stopping first.
- Never stop it suddenly, because withdrawal can be severe, even causing delirium, and the dose is usually lowered gradually.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Antidepressants like tranylcypromine can raise the risk of suicidal thoughts and behaviors in children, teens, and young adults, especially in the first few months or when the dose changes. Tranylcypromine is not approved for children. Watch closely for sudden changes in mood, behavior, thoughts, or feelings, and call your healthcare provider right away if you notice any.
It also carries a risk of hypertensive crisis, a sudden, severe rise in blood pressure. This can be set off by foods or drinks high in tyramine, or by certain drugs, during treatment or after stopping. Warning signs include sudden severe headache, nausea, vomiting, stiff neck, fast heartbeat, and heavy sweating. Avoid high-tyramine foods and drinks and have your blood pressure monitored.
Patient information guide A plain-language walkthrough of Tranylcypromine, written from its FDA label.
What Tranylcypromine is used for
▾
Tranylcypromine is used for one condition across its tablet products.
- Major depressive disorder (MDD) in adults who have not responded adequately to other antidepressants (Parnate, tranylcypromine tablets, and tranylcypromine sulfate tablets).
- Not for first-line treatment of MDD, because of serious side effects, drug interactions, and diet restrictions.
How Tranylcypromine works
▾
Tranylcypromine is a monoamine oxidase inhibitor (MAOI). It irreversibly blocks the enzyme monoamine oxidase (MAO) in the brain. This is thought to increase the activity of mood-related brain chemicals.
Its exact antidepressant action isn't fully understood.
Tranylcypromine dosage
▾
Tranylcypromine is taken by mouth as tablets, generally divided into more than one dose per day. Your prescriber may raise the dose gradually if your response isn't adequate, and may go slower if you're at risk for low blood pressure, such as older adults. Follow your prescriber and the label.
- Before starting, your prescriber should screen for a history of mania and measure your blood pressure.
- Don't stop suddenly. Withdrawal effects, including delirium, can occur, and the risk is higher with higher doses and longer use.
- Switching to or from other antidepressants requires waiting periods. Your prescriber will guide this.
Dosing details from the FDA-approved label
From the Tranylcypromine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Recommended dosage (adults; label does not name a specific indication in this text)
- 30 mg per day (in divided doses)
- If patients do not have an adequate response, increase the dosage in increments of 10 mg per day every 1 to 3 weeks
- Maximum: 30 mg twice daily (60 mg per day)
- Make dosage increases more gradually in patients at risk for hypotension (e.g., geriatric patients)
- Switching from contraindicated antidepressants to tranylcypromine
- After stopping a contraindicated antidepressant, allow 4 to 5 half-lives of the other antidepressant or any active metabolite before starting
- After stopping an MAO inhibitor antidepressant, allow at least one week or 4 to 5 half-lives of the other MAO inhibitor (whichever is longer)
- Switching from tranylcypromine to other MAOIs or contraindicated antidepressants
- After stopping tranylcypromine, at least one week should elapse before starting another MAOI (intended to treat MDD) or other contraindicated antidepressants
- Discontinuing treatment
- Consider discontinuing by slow, gradual dosage reduction
- Withdrawal effects, including delirium, reported with abrupt discontinuation; higher daily doses and longer duration of use appear associated with higher risk
Read the label’s full dosing text
2 DOSAGE & ADMINISTRATION Recommended daily dosage is 30 mg in divided doses (2.1) If no adequate response, increase dosage in increments of 10 mg per day every 1 to 3 weeks to a maximum dosage of 30 mg twice daily (60 mg per day).Consider more gradual dosage increases in patients at risk for hypotension (2.1) Consider discontinuing tranylcypromine sulfate tablets therapy gradually because of the risk for withdrawal effects ( 2.3 , 5.8 , 9.3 ) Switching from or to other MAOIs or other antidepressants: See full prescribing information for instructions ( 2.2 , 7.1 ) 2.1 Recommended Dosage Tranylcypromine sulfate tablets are for oral use. The recommended dosage is 30 mg per day (in divided doses). If patients do not have an adequate response, increase the dosage in increments of 10 mg per day every 1 to 3 weeks to a maximum 30 mg twice daily (60 mg per day). Dosage increases should be made more gradually in patients at risk for hypotension (e.g., geriatric patients) [see Warnings and Precautions (5.5)]. 2.2 Switching to or from Other Antidepressants Switching from Contraindicated Antidepressants to Tranylcypromine Sulfate Tablets After stopping treatment with contraindicated antidepressants, a time period of 4 to 5 half-lives of the other antidepressant or any active metabolite should elapse before starting treatment with tranylcypromine sulfate tablets. After stopping treatment with an MAO inhibitor antidepressant, a time period of at least one week or 4 to 5 half-lives of the other MAO inhibitor (whichever is longer) should elapse before starting treatment with tranylcypromine sulfate tablets to reduce the risk of additive effects [see Contraindications (4.1) and Drug Interactions (7.1)]. Switching from Tranylcypromine Sulfate Tablets to Other MAOIs or Contraindicated Antidepressants After stopping tranylcypromine sulfate tablets treatment, at least one week should elapse before starting another MAOI (intended to treat MDD) or other contraindicated antidepressants.Refer to the prescribing information of the subsequently used drug for product-specific advice on a medication-free interval [ see Contraindications (4.1) and Drug Interactions (7.1)]. 2.3 Discontinuing Treatment Withdrawal effects, including delirium, have been reported with abrupt discontinuation of tranylcypromine sulfate tablets therapy.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Tranylcypromine side effects
▾
The most common side effects reported in clinical trials include:
Common side effects
- Dry mouth
- Dizziness
- Trouble sleeping (insomnia)
- Sedation (sleepiness)
- Headache
- Overexcitement
- Constipation
- Blurred vision or tremor
When to get medical help
- New or worse depression, anxiety, agitation, panic attacks, or thoughts of suicide or dying
- Sudden severe headache, stiff or sore neck, nausea or vomiting, fast or pounding heartbeat, heavy sweating, or chest pain, which can signal a hypertensive crisis (a dangerous spike in blood pressure)
- Signs of serotonin syndrome: agitation, confusion, hallucinations, fever, sweating, tremors, stiff or twitching muscles, rapid pulse, seizures
- Extreme increase in activity or talking (mania)
- Fainting or severe dizziness when standing up
- Possible liver problems (hepatitis, raised liver enzymes)
- Seizures
- Withdrawal symptoms, including delirium, if stopped suddenly
Tranylcypromine warnings and precautions
▾
- Hypertensive crisis: a sudden, severe rise in blood pressure from tyramine-rich foods or certain drugs. It can lead to stroke and death.
- Suicidal thoughts and behaviors: a risk in children, teens, and young adults. It is not approved for children.
- Serotonin syndrome: a potentially life-threatening reaction with certain other medicines.
- Mania or hypomania: can be triggered in people with bipolar disorder.
- Low blood pressure and fainting: older adults are at higher risk.
- Surgery: blood pressure can drop or rise during anesthesia. Stopping before elective surgery is advised if possible.
- Liver problems, seizures, and low blood sugar in people with diabetes can occur.
Tranylcypromine interactions
▾
Many medicines and foods can interact seriously with tranylcypromine.
- Other MAOIs, SSRIs, SNRIs, and tricyclic antidepressants: risk of serotonin syndrome or hypertensive crisis.
- Amphetamines, methylphenidates, and decongestants like pseudoephedrine: risk of hypertensive crisis.
- Triptans, dextromethorphan, meperidine, tramadol, and others: risk of serotonin syndrome.
- Blood sugar medicines: may drop blood sugar too far.
- Blood pressure medicines and sedating drugs: may cause low blood pressure or extra drowsiness.
- Tyramine-rich foods such as aged cheese, cured meats, tap beer, and soy sauce: avoid during treatment and for 2 weeks after.
- Alcohol: not recommended.
The interaction risk lingers after stopping, because MAO activity takes time to recover.
Interactions listed in the FDA-approved label
From the Tranylcypromine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Other MAOIs and antidepressants (SSRIs, SNRIs, tricyclics, amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine, linezolid, intravenous methylene blue): Serotonin syndrome for all antidepressants; for MAOIs, increased MAO inhibition and risk of adverse reactions, serotonin syndrome, and hypertensive reaction. Contraindicated
- Amphetamines, methylphenidates and derivatives, and sympathomimetic drugs: Hypertensive reaction, including risk of intracerebral hemorrhage with sympathomimetic drugs. Contraindicated
- Triptans: Serotonin syndrome. Contraindicated
- Non-selective H1 receptor antagonists: Increased anticholinergic effects. Contraindicated
- Dietary supplements containing sympathomimetics: Listed as a clinically significant interaction with sympathomimetic-containing supplements. Contraindicated
- Agents with blood pressure-reducing effects and beta-adrenergic blockers: Hypotension; more pronounced bradycardia and postural hypotension with beta-blockers. Use with caution
- Blood glucose-lowering agents: Excessive reduction of blood glucose (additive effect). Dosage reduction of such agents may be necessary. Monitor blood glucose.
- CNS depressant agents (including opioids, alcohol, sedatives, hypnotics): Increased CNS depression. Use with caution
- Tyramine-containing foods and beverages: Tranylcypromine inhibits intestinal MAO, so large amounts of tyramine may enter the circulation and precipitate a sudden elevation in blood pressure or hypertensive crisis. Avoid foods and beverages with significant tyramine content during treatment or within 2 weeks of stopping treatment; concomitant alcohol is not recommended
- Individual products such as buspirone, carbamazepine, dextromethorphan, levodopa, meperidine, mirtazapine, tryptophan (Table 4): Hypertensive reaction or serotonin syndrome depending on the product (dextromethorphan also psychosis, bizarre behavior). Contraindicated
Read the label’s full interactions text
7 DRUG INTERACTIONS See Full Prescribing Information for a list of products, foods and beverages that can interact with tranylcypromine sulfate tablets (7) 7.1 Clinically Significant Drug Interactions Tables 3 and 4 lists drug classes and individual products, respectively, with a potential for interaction with tranylcypromine sulfate tablets, describes the predominant observed or anticipated risks, and provides advice on concomitant use. Given serious adverse reactions with multiple agents, patients should avoid taking over-the-counter medications or dietary supplements without prior consultation with a healthcare provider able to provide advice on the potential for interactions. Time to Start Tranylcypromine Sulfate Tablets after Discontinuation of a Contraindicated Drug For products that are contraindicated with tranylcypromine sulfate tablets, a time period of 4 to 5 half-lives of the other product or any active metabolite should elapse before starting treatment with tranylcypromine sulfate tablets. After stopping treatment with an MAO inhibitor antidepressant, a time period of at least 1 week or 4 to 5 half-lives of the other MAO inhibitor (whichever is longer) should elapse before starting treatment with tranylcypromine sulfate tablets because of the risk for clinically significant adverse reactions after discontinuation due to persistent MAO inhibition [see Dosage and Administration (2.2) , Warnings and Precautions (5.9) ] . This period can be several weeks long (e.g., a minimum of 5 weeks for fluoxetine given fluoxetine's long half-life). Refer to the prescribing information of the contraindicated product for relevant information. Time to Start Contraindicated Drug after Discontinuation of Tranylcypromine Sulfate Tablets The potential for interactions persists after discontinuation of tranylcypromine sulfate tablets until MAO activity has sufficiently recovered.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Tranylcypromine
▾
- Do not use with a pheochromocytoma or catecholamine-releasing paraganglioma.
- Tell your prescriber about high or low blood pressure, heart problems, stroke, headaches, liver or thyroid problems, seizures, or diabetes.
- Tell your prescriber about bipolar disorder, mania, or hypomania, in you or your family.
- Pregnancy: limited reports exist, and a potential fetal risk is advised. Tell your prescriber if pregnant or planning pregnancy.
- Breastfeeding: the drug passes into breast milk, and stopping breastfeeding is advised during treatment.
- Children: not approved, and safety and effectiveness are not established.
- Older adults: higher risk of postural hypotension, and cautious dosing is advised.
Tranylcypromine overdose
▾
An overdose can cause more severe, even fatal, versions of the usual side effects. These include agitation, confusion, seizures, very low or very high blood pressure with severe headache, and muscle rigidity with high fever. There is no specific antidote. Call poison control (1-800-222-1222) or go to the nearest emergency room right away. Effects can be delayed, so close observation for at least 1 week is advised.
What Tranylcypromine does in the body
▾
Tranylcypromine is eliminated from the body within about 24 hours. However, MAO enzyme activity takes up to 3 to 5 days to recover. For this reason, interaction risks continue after you stop the medicine.
How to store Tranylcypromine
▾
Store between 15° and 30°C (59° and 86°F). Dispense in a tight, light-resistant container.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Tranylcypromine
81 supplements and herbal products have documented interactions with Tranylcypromine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 14
- Moderate · 55
- Minor · 12
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Tranylcypromine has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Tranylcypromine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Tranylcypromine — the kind of thing our pharmacy team would talk through with you at the counter.
What is tranylcypromine used for?
▾
Do I really have to watch what I eat?
▾
Can I take cold or allergy medicine with it?
▾
What side effects should I expect?
▾
Can I stop it if I feel better?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Tranylcypromine available over the counter?
▾
When was Tranylcypromine first available?
▾
Who makes Tranylcypromine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Tranylcypromine on HelloPharmacist
Tranylcypromine forms and strengths (how it comes)
Tranylcypromine is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Tranylcypromine inactive ingredients by manufacturer.
Tablet
How this form is used
- Parnate is used for major depressive disorder in adults who have not responded adequately to other antidepressants.
- Tranylcypromine tablets are used for major depressive disorder in adults who have not responded adequately to other antidepressants.
- Tranylcypromine sulfate tablets are used for major depressive disorder in adults who have not responded adequately to other antidepressants.
- Parnate tablets are for oral use, usually in divided daily doses.
- Tranylcypromine tablets are for oral use, usually in divided daily doses.
- Tranylcypromine sulfate tablets are for oral use, usually in divided daily doses.
- Parnate, tranylcypromine tablets, and tranylcypromine sulfate tablets should be stopped gradually rather than suddenly, as directed by a prescriber.
Tranylcypromine on the U.S. market: products, makers and brands
How Tranylcypromine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
6 companies list 6 Tranylcypromine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1961. Brand names on the directory include Parnate; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (1) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Tranylcypromine is used (Medicaid data)
A general measure of how commonly Tranylcypromine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Tranylcypromine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Tranylcypromine prescribed? Of the 1,601 medications we measure, Tranylcypromine ranks #1,318 by Medicaid prescriptions — more than 18% of them.
Utilization by Tranylcypromine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
tranylcypromine 10 MG Oral Tablet
Summed across the 3 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 313447
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Tranylcypromine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 10 listed Tranylcypromine NDCs with Medicaid activity.
Compare Tranylcypromine products
A representative set of FDA-listed product records for Tranylcypromine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 10 mg | Oral | Actavis Pharma, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg | Oral | Advanz Pharma (US) Corp. | NDA | View NDC → |
| 10 mg | Oral | Novitium Pharma LLC | ANDA | View NDC → |
| 10 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 10 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 10 mg | Oral | Strides Pharma Science Limited | ANDA | View NDC → |
Showing 6 of 6 products — FDA National Drug Code Directory. See every product, package size and price: browse all 6 Tranylcypromine NDCs →
Tranylcypromine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tranylcypromine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tranylcypromine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Tranylcypromine FDA approval history
How Tranylcypromine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Tranylcypromine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Tranylcypromine recalls since July 2021.
✅No Tranylcypromine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 10734 1 dose form · 1 strength
-
Dose form (SCDF) Oral Tablet RxCUI 374182In current FDA listingsClinical drug / strength (SCD) 10 MGRxCUI 313447
Look up RxCUI 10734 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Tranylcypromine supply and shortage status
Whether Tranylcypromine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Tranylcypromine costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 10 mg | $0.591 per tablet | NDC details & price history |
| Tablet · Oral | 10 mg | $0.591 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Tranylcypromine brand names
Tranylcypromine is sold under one brand name in the FDA directory — Parnate. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Tranylcypromine: manufacturers and labelers
6 companies list Tranylcypromine products with the FDA. By number of product records, the largest are Actavis Pharma, Inc., Advanz Pharma (US) Corp., Novitium Pharma LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Tranylcypromine drug class (RxNorm)
Tranylcypromine belongs to the Monoamine Oxidase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Tranylcypromine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Solco Healthcare US, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →